$2.45T
Total marketcap
$133.66B
Total volume
BTC 49.76%     ETH 16.78%
Dominance

Soligenix SNGX Stock

0.77 USD {{ price }} 5.075446% {{change_pct}}%
Exchange
NasdaqCM
Market Cap
8.06M USD
LOW - HIGH [24H]
0.66 - 0.77 USD
VOLUME [24H]
294.85K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-1.46 USD

Soligenix Price Chart

Soligenix SNGX Financial and Trading Overview

Soligenix stock price 0.77 USD
Previous Close 0.74 USD
Open 0.73 USD
Bid 0 USD x 4000
Ask 0 USD x 1400
Day's Range 0.72 - 0.74 USD
52 Week Range 0.65 - 15 USD
Volume 91.81K USD
Avg. Volume 892.26K USD
Market Cap 5.81M USD
Beta (5Y Monthly) 1.766901
PE Ratio (TTM) N/A
EPS (TTM) -1.46 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 29.88 USD

SNGX Valuation Measures

Enterprise Value 4.95M USD
Trailing P/E N/A
Forward P/E -0.4111494
PEG Ratio (5 yr expected) -0.36
Price/Sales (ttm) 5.703272
Price/Book (mrq) N/A
Enterprise Value/Revenue 4.86
Enterprise Value/EBITDA -0.406

Trading Information

Soligenix Stock Price History

Beta (5Y Monthly) 1.766901
52-Week Change -91.57%
S&P500 52-Week Change 20.43%
52 Week High 15 USD
52 Week Low 0.65 USD
50-Day Moving Average 1.13 USD
200-Day Moving Average 5.73 USD

SNGX Share Statistics

Avg. Volume (3 month) 892.26K USD
Avg. Daily Volume (10-Days) 115.47K USD
Shares Outstanding 8.12M
Float 8.08M
Short Ratio 0.07
% Held by Insiders 0.36%
% Held by Institutions 7.18%
Shares Short 171.18K
Short % of Float 2.10%
Short % of Shares Outstanding 2.10%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:15

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -1198.12%
Gross Margin 32.74%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -43.84%
Return on Equity (ttm) -656.49%

Income Statement

Revenue (ttm) 1.02M USD
Revenue Per Share (ttm) 0.35 USD
Quarterly Revenue Growth (yoy) 36.79%
Gross Profit (ttm) N/A
EBITDA -12186842 USD
Net Income Avi to Common (ttm) -10495427 USD
Diluted EPS (ttm) -3.2
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 10.27M USD
Total Cash Per Share (mrq) 1.27 USD
Total Debt (mrq) 9.22M USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 0.942
Book Value Per Share (mrq) -1.156

Cash Flow Statement

Operating Cash Flow (ttm) -11576431 USD
Levered Free Cash Flow (ttm) -9151346 USD

Profile of Soligenix

Country United States
State NJ
City Princeton
Address 29 Emmons Drive
ZIP 08540
Phone 609 538 8200
Website https://www.soligenix.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 13

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Q&A For Soligenix Stock

What is a current SNGX stock price?

Soligenix SNGX stock price today per share is 0.77 USD.

How to purchase Soligenix stock?

You can buy SNGX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Soligenix?

The stock symbol or ticker of Soligenix is SNGX.

Which industry does the Soligenix company belong to?

The Soligenix industry is Biotechnology.

How many shares does Soligenix have in circulation?

The max supply of Soligenix shares is 10.52M.

What is Soligenix Price to Earnings Ratio (PE Ratio)?

Soligenix PE Ratio is now.

What was Soligenix earnings per share over the trailing 12 months (TTM)?

Soligenix EPS is -1.46 USD over the trailing 12 months.

Which sector does the Soligenix company belong to?

The Soligenix sector is Healthcare.

Soligenix SNGX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16274.94 USD
+1.14
4.86B USD 16096.6 USD 16302.24 USD 4.86B USD
NASDAQ Capital Market Composite RCMP 122.82 USD
+1.7
120.85 USD 122.96 USD
NASDAQ HealthCare IXHC 1018.62 USD
+2.02
1001.06 USD 1021.85 USD